Semnur signs binding term sheet for $100M strategic investment from iHolding Group at $10/share

Semnur Pharmaceuticals, Inc.

iHolding to purchase $100M of newly issued common stock at $10/share (~10M shares).
Proceeds to fund SEMDEXA Phase 3 program, product development, acquisitions, working capital.
Investment subject to due diligence, definitive agreements, board/stockholder/regulatory approvals.
Semnur is a majority-owned subsidiary of Scilex Holding Company.
No assurance of consummation; risks of termination or litigation.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.